A panel of its expert advisers voted against the drug, and some panel members resigned. In July, the FDA asked the Office of the Inspector General for the Department of Health and Human Services to open an investigation into interactions with Biogen related to the approval of the drug. U.S. lawmakers have also launched an investigation into the drug. Since the launch, sales of Aduhelm have been slow and Biogen cut the price by 50% in December.